Seer (SEER) Non-Current Deffered Revenue (2020 - 2021)

Seer (SEER) posted quarterly Non-Current Deffered Revenue of $2.7 million for Q3 2021, up 19.53% quarter-over-quarter from $2.2 million in Q2 2021.

Seer (SEER) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Seer's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $2.7 million for Q3 2021.

In Q3 2021, Non-Current Deffered Revenue changed N/A year-over-year to $2.7 million; the TTM figure through Sep 2021 stood at $2.7 million (changed N/A YoY), while the FY2020 annual figure was $1.9 million, changed N/A from the prior year.
Non-Current Deffered Revenue for Q3 2021 stood at $2.7 million, up from $2.2 million in the prior quarter.
The five-year high for Non-Current Deffered Revenue was $2.7 million in Q3 2021, with the low at $1.9 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Seer	230.63 Mn	230.63 Mn	1.51 Mn	-

Download Data